CEACAM5 and breast carcinoma: In addition, administration of 221 and 222 (both given at 50 mg/kg for 14 days by gastric intubation) in a 7,12-dimethylbenz[a]anthracene-induced rat mammary carcinoma model caused a reduction of cancer markers (carcinoembryonic antigen and cancer antigen 15–3) and resulted in lower levels of the liver enzymes aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase compared to rats in the mammary carcinoma control group.